Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:51:34.298Z.
Calculation as of: 2026-10-06T21:51:34.298Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2d15fccd73dd71321fa30efb235d10704747171fee005d1a5dd6499fafc6c703
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$18.65M
EV/EBIT Ratio
N/A
TTM Avg
624.43x
3Y Avg
624.43x
5Y Avg
624.43x
Market Cap
$17.39M
EV/EBIT Ratio
N/A
TTM Avg
64.12x
3Y Avg
126.81x
5Y Avg
126.81x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | $18.30M | N/A | N/A | N/A | N/A |
| P3 Health Partners Inc. (PIII)vs › | $18.41M | N/A | N/A | N/A | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.65M | N/A | 624.43x | 624.43x | 624.43x |
| Cosmos Health Inc. (COSM)vs › | $17.39M | N/A | 64.12x | 126.81x | 126.81x |
| Lipocine Inc. (LPCN)vs › | $17.31M | N/A | 19.21x | 19.21x | 19.21x |
| Actuate Therapeutics Inc (ACTU)vs › | $19.42M | N/A | N/A | N/A | N/A |
| PAVmed Inc. (PAVM)vs › | $17.07M | N/A | N/A | N/A | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | N/A | N/A | N/A | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $19.77M | N/A | N/A | N/A | N/A |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.82M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
